GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Total Liabilities

Biocon (NSE:BIOCON) Total Liabilities : ₹307,959 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Biocon Total Liabilities?

Biocon's Total Liabilities for the quarter that ended in Mar. 2024 was ₹307,959 Mil.

Biocon's quarterly Total Liabilities declined from Sep. 2023 (₹302,995.00 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹307,959.00 Mil).

Biocon's annual Total Liabilities increased from Mar. 2022 (₹109,240.00 Mil) to Mar. 2023 (₹295,540.00 Mil) and increased from Mar. 2023 (₹295,540.00 Mil) to Mar. 2024 (₹307,959.00 Mil).


Biocon Total Liabilities Historical Data

The historical data trend for Biocon's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Total Liabilities Chart

Biocon Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70,607.00 100,147.00 109,240.00 295,540.00 307,959.00

Biocon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 295,540.00 - 302,995.00 - 307,959.00

Biocon Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biocon's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=153588+(134248+20123
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=307,959

Total Liabilities=Total Assets (A: Mar. 2024 )-Total Equity (A: Mar. 2024 )
=560707-252748
=307,959

Biocon's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=153588+(134248+20123
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=307,959

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=560707-252748
=307,959

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocon Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biocon's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocon (NSE:BIOCON) Business Description

Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560 100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.

Biocon (NSE:BIOCON) Headlines

No Headlines